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In order to assess the potential of electromagnetic fields (EMF) to influence the process of
carcinogenesis, it will be necessary to supplement epidemiological studies with controlled
laboratory studies in animals. There are now a number of suitable assays available that focus on
different histopathological forms of cancer and on different stages of carcinogenesis-induction,
promotion, progression. In this review we discuss eight major systems in the context of this
generalized carcinogenesis paradigm. Our aim is to bring together what is currently known about
the biology of carcinogenesis in these systems in order to provide a context for evaluating EMF
results as they become available. We also critically discuss EMF test results that have so far been
obtained in the animal models reviewed. Most of the 19 completed studies identified were
negative. However, suggestive positive results were reported in three promotion assays (in rat
mammary gland, in rat liver, and in mouse skin), and in one multigeneration study in mice. Results
in the rat liver assay and in the multigeneration study have only been reported in abstract form
and cannot be adequately evaluated. Positive results reported in both the rat mammary gland and
the mouse skin systems are of weak statistical significance and have not been independently
replicated. However, it may be of interest that effects in both systems appear primarily to involve
the progression stage of carcinogenesis. We suggest that more definitive conclusions as to the
carcinogenic potential of EMF may require expanded test protocols that reinforce traditional
carcinogenesis end points with biochemical or other parameters reflective of biological processes
known to be associated with carcinogenesis in the different systems. Environ Health Perspect
105(Suppl 1):81-103 (1997)
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Introduction
Over the past decade, considerable research Sagan (2); also see more recent studies by
has addressed the question of whether Floderus et al. (3), Sahl et al. (4), and
exposure to electric and/or magnetic fields Loomis et al. (5)].
(EMF) is a risk factor for cancer. Interest in Though these epidemiologic data are
this question has been triggered primarily by suggestive, the carcinogenic potential of
residential and occupational epidemiology EMF is still uncertain. As has been the case
studies that have suggested an association with numerous environmental chemicals
between EMF exposure and a variety of and physical agents, definitive conclusions
cancers [e.g., see reviews by Bates (1) and as to the potential carcinogenicity of EMF
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are likely to require supporting evidence
from whole animal carcinogenesis bioas-
says along with a greater understanding of
relevant biological mechanisms.
The carcinogenic potential of EMF is
currently being evaluated worldwide in
diverse animal model systems, including
2-year chronic carcinogenesis bioassays
and a variety ofother, usually shorter term,
in vivo assays aimed primarily at examining
postinitiation events.
In this review, we discuss the biology of
eight major model systems and attempt to
clarify the relationship ofeach to the com-
plex process that we term carcinogenesis.
Recent reviews of carcinogenesis mecha-
nisms can be found in Weinstein (6),
Weinberg (7), Harris (8), and Barrett (9).
Carcinogenesis, though incompletely
understood, is usually described in terms of
an initiation-promotion-progression para-
digm. In this construct, cells that incur one
or more genotoxic insults at a critical locus
(initiation) may, relative to normal neigh-
boring cells, selectively proliferate into an
expanded clone under the nongenotoxic
(epigenetic) influence(s) of endogenous
growth factors or additional environmental
exposures (promotion). Subsequent exposure
to genotoxic agents or stochastic genetic
errors within the affected tissue would lead
to malignancy (progression) (8,10).
The model systems reviewed reflect a
range ofassays targeted at different stages
ofthis generalized paradigm. Our aim is to
provide a biological context for the inter-
pretation ofEMF test results from the per-
spective of the biology of the model
systems, their relationship to the general
paradigm ofcarcinogenesis, and their rele-
vance to human cancer. As they are avail-
able, we will assess results from tests of
EMF using the model systems reviewed;
see also Hardell et al. (11) for a recent
review ofEMF animal test results.
Throughout this paper, physical para-
meters are given in Standard International
(SI) units. Magnetic flux density is
expressed in units oftesla (T); electric field
strength in volts/meter (V/m). Alternating
current (ac) fields cited are sinusoidal unless
otherwise noted.
Models ofCarcinogenesis
The model systems reviewed are listed in
Table 1. In addition to long-term chronic
carcinogenesis bioassay protocols in rats
and mice, there are a number ofprotocols
targeted at the promotion or progression
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Table 1. Multistage animal models reviewed.
Model
Rat mammary/DMBA (or NMU)
Rat liverfoci/DEN
Mouse skin/DMBA
Mouse lymphoma/
X-irradiation
Leukemia/cell transplant
Transgenic models
(ENU/Pim-1 and p53)
Rat brain/ENU
transplacental
2-year chronic
bioassays
Methodological references
and key reviews
Huggins and Yang ( 12)
Welsch (13)
Russo et al. (14,15)
Nandi etal. (16)
Farber(209)
Pereira (54)
Pitot (51)
Dragan and Pitot (52)
Eastin (63)
DiGiovanni (61,62)
Yuspa (60)
Kaplan and Brown (93)
Janowski et al. (101)
Boniver etal. (102)
Muto et al. (103)
Stromberg (111)
Stromberg et al. (113)
Martens and Hagenbeek (118)
Dieter etal. (114)
Schepartz(127)
Geran et al. (97)
Venditti (96)
Adams and Cory (134)
Hanahan(135)
Breuer et al. (98)
Donehower and Bradley (150)
Kleihues et al. (172)
Maekawa and Mitsumori (174)
Peterson et al. (171)
Sontag et al. (192)
Bannasch et al. (193)
EMFTestsa
Completed
Beniashvili et al. (39)
Mevissen et al. (40,41,42,46)
Loscher et al. (34,43)
L-scher and Mevissen (45)
Baum et al. (44)
LeBars et al. (207)b
Leung et al. (208)b
In progress
Sasser et al. (50)
Completed
Rannug et al. (57-59)
Completed
Stuchly et al. (78,80)
McLean et al. (79,81,82)
Rannug etal. (76,77)
Byus et al. (83)
Morris et al. (84)
DiGiovanni et al. (85)
Completed
Svedenstal and Holmberg (108)
In progress
Babbitt et al. (109)
Completed
Sasser et al. (131,132)
Thomson et al. (133)
Completed
McCormick et al. (168)
In progress
Repacholi et al. (169)
Completed
Brugere et al. (190)
In progress
Mandeville et al. (188,189)
Completed
Yasui et al. (196-198)
Fam and Mikhail (199)
Mikhail and Fam(200,201)
In progress
Mandeville et al. (188,189)
McCormick et al. (195)
'All studies involve extremely low frequency, direct current, or pulsed magnetic fields exposures except as indi-
cated. bElectric field studies.
stages ofcarcinogenesis. The protocol char-
acteristics of these assays are shown in
Table 2. The rat 7,12-dimethylbenz[a]-
anthracene (DMBA)/mammary carcinoma
model, the rat liver foci model, and the
mouse skin two-stage model have been
widely used in mechanistic studies as well
as in tests for potential promoter activity.
The mouse lymphoma/X-irradiation, rat
leukemia/cell transplant, rat brain/N-ethyl-
N-nitrosourea (ENU), and two transgenic
models have been less widely used to test
agents for potential postinitiation effects,
but are well-established models used in
mechanistic studies or in tests ofpotential
chemotherapeutic agents.
RatMammaryCarinomaModel
More than 30 years ago, Charles Huggins
developed what is today the most widely
used animal model for human breast cancer
(12). The system has been comprehen-
sively reviewed (13-15). Briefly, mammary
tumors (adenocarcinomas and fibroade-
nomas) develop in rats given low doses
of initiator, usually DMBA or N-methyl-
N-nitrosourea (MNU), followed by chronic
treatment with a promoter. Maximal sensi-
tivity to the initiator treatment is coinci-
dent with the period ofsexual maturation,
about 6 to 8 weeks ofage, when the target
tissue experiences a high rate of growth.
Experiments are usually terminated about
3 months after initial exposure to the ini-
tiator. Results are determined by morpho-
logical and histological examination and
are usually reported as tumor incidence,
tumor size or weight, tumor latency, and
tumors per tumor-bearing animal.
The rat mammary carcinoma model has
been considered an adequate system in
terms of its relevancy in many respects to
human disease (15). For example, factors
that promote tumor development in the rat
mammary model, such as reproductive
status, also increase breast cancer risk in
humans. However, other aspects of the
rodent system suggest that comparisons
between rodents and humans should be
made with caution. Aside from obvious dif-
ferences between rats and humans, such as
different numbers ofmammary glands and
different cycle lengths (4 vs 28 days), there
are a number ofmore subde biological dif-
ferences that could affect the validity ofrisk
extrapolations. For example, the pattern of
hormonal sensitivity of mammary tumors
in rats and humans is quite different [see
Nandi et al. (16) for a recent review].
Though both human and rat breast tumors
are hormonally dependent, human tumors
are sensitive primarily to estrogens (17) and
DMBA-induced tumors in rats are sensitive
primarily to prolactin (13). These hor-
mones act through quite different receptor-
mediated pathways [discussed in Lucier
(18) and Welsch (13)]. Therefore, modula-
tion oftumor response in the rodent system
by a mechanism involving the prolactin
pathwaywould not necessarily imply a sim-
ilar result on tumor development in the
human system. On the other hand, MNU-
induced rodent mammary tumors are less
dependent on prolactin and slightly more
sensitive to the direct stimulatory effects of
estrogen, suggesting they may be more
akin to human breast tumors than DMBA-
initiated mammary tumors (19).
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Table 2. Promoter assay protocols.a
Leukemia/
Mouse lymphoma/ Cell transplant Transgenic
Rat mammary/DMBA Rat liverfoci/DEN Mouse skin/DMBA X-irradiation (LGL, P388) (ENU/Pim-1, p53) Rat brain/ENU
Species/ Rat/Sprague-Dawley Rat/Sprague-Dawley Mouse/SENCAR Mouse/C57BI, CBA Rat/F344 (LGL) Mouse/PiKM- Rat/F344
strain NMRI Mouse DBA/2 (P388) orTSG-p53
Mitogen Partial hepatectomy
Initiator(s) DMBA, NMU DEN DMBA X-irradiation Transplantation of ENU (Pirrml ENU, MNU
leukemic cell lines system) (administered
neonatally)
Co-promoter PB TPA
End points Adenocarcinoma AHF(usually GST-P Papilloma Lymphoma/ Leukemia Lymphoma CNS neoplasms-
Fibroadenoma or GGT) Squamous cell leukemia mixed gliomas
carcinoma and oligoden-
drogliomas
Duration 3 months 3 months 20weeks 131 weeks 70 days(LGL) 6 months 20weeks
2D-30 days (P388) (microtumor
evaluation);
lifetime
Method of Morphological Histological Morphological Histopathologic Hematological Morphological Clinical
evaluation Histological Histochemical Histological Immunohistologic Biochemical neurological
Immunohisto- Morphological Histopathology
chemical
Parameters Tumor incidence Foci/cm3 Time to firsttumor Tumor incidence Survival, bodyweight Tumor incidence % Animals with
reported Tumor size or Mean focus area % Tumor-bearing Time to first tumor Spleen weight Tumor latency tumors
weight % volume occupied animals White blood cell count
byfoci Tumors/animal Hematological indices
aFor references see Table 1 and text.
Interpreting the relevance to humans of
results in the rat DMBA model system can
also be complicated because some tested
substances may not only interact with
mammary tumor pathogenesis, but also
may interact with other factors unique to
the model system. For example, mutations
in the p53 tumor suppressor gene are the
most frequently observed genetic lesions in
human breast cancers. However, this gene
does not appear to be altered in most
DMBA-induced mammary tumors (20).
Also, in the mammary carcinoma model,
DMBA itselfaffects serotonin (21), mela-
tonin (22,23), and NK (natural killer)
function (24), all of which could have
some involvement in subsequent tumor
development. Interaction of promoting
agents with the expression ofsuch DMBA-
initiated events may therefore not be gen-
eralizable to other systems that do not
utilize DMBA.
The literature on tumor promotion in
this model system is extensive [see reviews
by Welsch (13) and Russo et al. (14)] and
indicates that the system is highly sensitive
to modulation oftumor development and
growth by both endogenous and exogenous
substances. Table 3 lists 37 substances or
physiological states that act as promoters in
this rodent model system. As discussed
above, a significant fraction of mammary
tumors are hormone sensitive. Estrogens,
progesterone, prolactin, and other estrogen-
related substances enhance tumor growth
rate and incidence. Physiological states that
increase serum levels of these hormones,
particularly prolactin, also appear to
enhance tumor development. Examples are
reproductive status (i.e., pregnancy or
pseudopregnancy enhances tumor growth),
interference with normal circadian rhythms
(i.e., constant light increases serum levels of
prolactin and increases tumor growth), and
even different mental states. For example
there is a rapid increase in serum prolactin
levels during meditation [reviewed in
Jevning et al. (25)] and certain types of
stress result in an increase in prolactin
secretion. Other endogenous substances,
such as insulin, or dietary factors, such as
high levels ofpolyunsaturated fatty acids,
carbohydrates, and proteins, also have been
observed to enhance tumorgrowth. In addi-
tion, miscellaneous drugs such as haloperi-
dol, perphenazine, and reserpine have
demonstrated promoter activity in the rat
model. It should be noted that, as indicated
in Table 3, evidence for the promoting
potential of a number of the listed sub-
stances is either conflicting or controversial.
In this system, the exquisite sensitivity
of tumor development to modulation is
underscored by the observation that there
are also a variety ofsubstances, both exoge-
nous and endogenous, that inhibit tumor
growth. One ofthese substances, the neu-
rohormone melatonin, is of particular
interest because it has been suggested that
EMF could act as a promoter bydecreasing
serum melatonin levels (26). Melatonin is
well documented to be oncostatic for
mammary cancer. With apparently only
one exception (27), all groups that have
examined effects ofexogenous melatonin
treatment on tumor growth in DMBA-
induced rats have observed an inhibition of
tumor growth (28-31).
Effects of magnetic fields (MFs) on
melatonin are less certain. These studies
have recently been reviewed (32,33).
Though there is uncertainty regarding
effective exposure conditions and difficulty
in reproducing results, reports from several
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Table 3. Examples of promoters in the rat mammary/
DMBA assay.a
Hormones and adrenal steroids
Estrogensb
Estradiol
Progesterone
Enovidb.c
Prolactin
Growth hormonec
Pregnancy
17-Deoxycorticosteroid
Neuroendocrine system status
Drugsthat decrease hypothalamic dopaminergic
activity(reserpine, perphenazine, sulpiride,
fluphenazine, methyldopa, pimozide, a-methyl
paratyrosine, haloperidol)
Stressc
Thyrotropin-releasing hormone
Thyroid status
Both hyperthyroid-inducing drugs(thyroxine, tri
iodothyronine) and hypothyroid-inducing agents
(goitrogens, 1311,propylthiouracil) have been
reported as promoters, but results are controversial
Fats, proteins, and carbohydrates
Dietaryfat(210-212)
Dietary proteinc
Sucrose
Immune status
Bacillus Calmette-Guerinc
Miscellaneous
Caffeine
Ethanol (213)
Iron deficiency (214)
Glucose
Insulin
'Agents listed are those which have been observed to
promote the growth of DMBA-induced mammary carci-
nomas in rats. Agents observed to inhibittumor growth
or which had no effect are not included. Most reports
cited employed Sprague-Dawley rats and used 7,12-
dimethylbenz[a]anthracene as inducer. Unless another
reference is specified, all promoters listed are from
Welsch's comprehensive review (13). bWhereas low
doses of these agents stimulate the growth of DMBA-
induced mammary carcinomas, high doses can inhibit
growth [seeWelsch (13)1. cResults areconflicting.
laboratories (34-38) suggest that under
certain conditions, MF exposure may
decrease serum melatonin in rodents. In
humans, the concentration ofplasma mela-
tonin was not reduced after nocturnal
exposure to a 0.02 mT intermittent MF
(C. Graham et al., in press).
Tests ofMagnetic Fields Using the
Mammary ModeL Beniashvili et al. (39)
reported an increased incidence (p<0.05)
ofmammary adenocarcinomas in MNU-
treated rats (strain unspecified) exposed 2
days after MNU treatment for 3 hr/day for
2 years either to 50-hertz (Hz) ac or dc
MFs of20 pT. In the same exposure groups,
a decrease in latency was also reported, but
statistical significance was not calculated.
Table 4. Summaryofresults reported bythe L6scher groupfor 50-Hz ac magnetic fields.
Reference controls Sham controls MFexposed
Fluxdensity with tumors, % with tumors, % withtumors, % p-value Reference
0.3-1.0 pT - 58 58 NS (40)
0.3-1.0 pTa - 61a 67a NSa (34,41)a
10 pTa - 62a 69a NSa (42)a
50pTa - 55a 69a P<0.05a (46)a
100 pTa - 34a 52a p < 0.05a (43,44)a
30,000 pT 67 56 78 NS (40)
30,000 pT 56 50 40 NS (40)
NS, notstatistically significant. Table entries used forthe correlation analysis in Loscherand Mevissen (45).
Significant increases were not observed in
rats exposed to the MF for 0.5 hr/day.
Most work with this system is from
Loscher and his colleagues (34,40-46). In
all experiments, female Sprague-Dawley
rats 6 to 8 weeks ofage were exposed by
gavage to DMBA (four weekly doses at 5
mg/rat/dose) beginning on the first day of
MF exposure. MF exposure was 24 hr/day,
7 days/week for 13 weeks. Except as indi-
cated, there were 99 animals in each expo-
sure and sham-exposed group. Exposed and
sham-control groups were sacrificed at the
end ofthe exposure period and the number
and size of morphologically detectable
tumors were determined.
In an early experiment, small groups of
animals (18 in each group) were exposed
either to 15-mT dc or 30-mT 50-Hz fields
(40). Two separate experiments were
performed using 30-mT 50-Hz fields.
Tumor incidence andweight were reported
at the end of the exposure period. In
the 15-mT direct current experiment,
investigators report a greater than 4-fold
increase (p<0.05) in the weight oftumors
in exposed animals compared to sham-
exposed controls, but no significant increase
when compared to reference controls (age-
matched rats treated with DMBA but
housed in a separate area). There was also
no significant difference in tumor incidence
in MF-exposed animals when compared to
either sham-exposed or reference controls.
This experiment was evidently not repeated.
There was also a statistically significant
increase (p<0.05) in the number oftumors
(adenocarcinoma) per tumor-bearing ani-
mal when compared to the reference con-
trol, but not when compared to the sham
control, in one ofthe two 30-mT ac expo-
sure experiments. The other 30-mT experi-
ment was negative, as were the combined
results ofthe two experiments. A statisti-
cally significant difference in tumor inci-
dence between exposed and sham-exposed
groups was not observed in either of the
30-mT experiments. As the authors point
out, however, the group sizes were very
small, limiting the powerofthe assay.
L6scher and Mevissen have recently
reported a highly significant (r= 0.99,
p<0.01) linear correlation between flux
density and tumor incidence (45). This
correlation is a summary analysis ofdata
compiled from separate experiments con-
ducted over a period of several years.
Below, we will review results from each
experiment used for the correlation and
then comment on the summary correlation
analysis. To assist this discussion, we have
reproduced the flux densities tested and the
tumor incidences reported in Table 4.
As shown in Table 4, results of two
experiments at the 0.3 to 1.0 pT flux den-
sityhave been reported (34,40,41). In each
experiment, a group of36 rats was exposed
to the gradient ac sine wave 50-Hz field
and a group of36 was exposed to a sham
field. Nocturnal serum melatonin was sig-
nificantly reduced by this exposure, but no
statistically significant differences in tumor
size, incidence, or histopathology were
observed in MF-exposed groups as com-
pared to sham-exposed groups. The inves-
tigators caution that results are limited by
the relatively small number ofanimals used
in the study.
In abstract form, Mevissen et al. (42)
report that exposure to a 10-pT flux den-
sity produced no significant differences in
tumor incidence or tumor size in MF-
exposed animals compared to sham-
exposed controls. Tumor incidence in the
MF-exposed group was 69% and tumor
incidence in sham-exposed controls was
62%. The investigators indicate a tendency
toward decreased latency in the MF-
exposed group but do not present data. In
this experiment, small groups (n= 9) of
animals were also MF- and sham-exposed
in the absence ofDMBA. No tumors were
found in either ofthese two groups.
Results at 50 pT have recently been
published (46). Investigators indicate that
tumor incidence in the MF-exposed group
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was 25.5% above the concurrent sham-
exposed control at autopsy (55% in sham-
exposed controls and 69% in MF-exposed
animals). In a separate publication, the
same laboratory (47) reported that this
flux density (50 pT) also results in a statis-
tically significant (p<0.01) increase in the
mammary gland in ornithine decarboxylase
(ODC), an enzyme associated with cell
proliferation. They indicate that this obser-
vation strengthens their hypothesis that
weak 50-Hz magnetic fields promote or co-
promote carcinogenesis in the rat mammary
model system.
Loscher et al. (43), using 50-Hz,
100-pT exposures, reported statistically sig-
nificant increases (p<0.05) in the incidence
ofmammary tumors (as determined by pal-
pation) in MF-exposed animals compared
to sham-exposed controls. The difference
was observed as soon as 8 weeks after
DMBA application and was maintained
throughout the 3-month experiment. At
termination ofthe experiment, tumor inci-
dence in the MF-treated group was 52%,
versus 34% in sham-exposed controls. A
statistically significant (p<0.05) increase in
tumor size (as estimated by palpation) was
also reported at the end of the exposure
period, though not at earlier time points.
The average of tumor volumes for MF-
exposed animals was also greater than the
sham-exposed group, but the difference was
not statisticallysignificant.
Recently, Baum et al. (44), supplied
additional analysis ofdata obtained in the
100-pT study (43); they include a detailed
histopathological analysis and additional
control groups. Investigators report that the
increases previously reported in the MF-
exposed group were primarily due to effects
on tumor growth and malignancy rather
than on tumor incidence. Specifically, if
macroscopically visible mammary tumors
were considered, the difference in tumor
incidence between MF-exposed and sham-
exposed rats reported previously (43) was
observed. However, when the analysis was
extended to include a microscopic histo-
pathological analysis that included non-
neoplastic as well as neoplastic lesions, no
statistically significant differences were
observed between MF-exposed and sham-
exposed controls.
Evaluation of the linear correlation
offered by the Loscher group in its most
recently published study (45) is complex
primarily because, as noted previously,
results for each data point were obtained in
different experiments conducted at differ-
ent times with different groups ofanimals.
Indeed, as shown in Table 4, the sham-
control tumor incidences reported range
from 34 to 62%, a substantially wider
range than the MF-exposed tumor inci-
dences used for the correlation (52-69%).
It is true, as Loscher has pointed out (48),
that variation in control incidence among
different animal groups is expected, and
that differences between concurrent control
and exposed groups are more significant
than differences between exposed inci-
dences and historical control averages.
Nevertheless, it is ofsome concern that the
100-pT tumor incidence value (52%), on
which the correlation largely depends, is
actually less than the average ofthe seven
sham-control tumor incidences reported in
Table 4 (53.9%). It is also ofsome concern
that this 100-pT tumor incidence is so
much less than all but one ofthe other MF-
exposed tumor incidences reported in Table
4; see also the comments ofIrnich (49).
Summary. All rat mammary assays are
summarized in Table 5. The positive
results reported by Loscher et al. (43),
Baum et al. (44), and Mevissen et al. (46)
at two flux densities (50 and 100 pT) and
by Beniashvili and colleagues at 20 pT
(39) suggest the possibility ofa promoting
effect of MF-exposure at these low flux
densities. Though there were significant
differences in the protocols employed by
these two groups (e.g., different inducers
and different exposure periods), both
reported significant increases in more than
one tumor-associated parameter. However,
results are not highly statistically significant
and, as discussed above, there was consid-
erable variability in tumor incidence rates.
In interpreting the potential significance of
these results it is also important to keep in
mind the sensitivity ofthe DMBA/mam-
mary system to modulation by many
dietary and other endogenous factors
(Table 3). Further investigation with this
model may help to clarify results. The U.S.
National Toxicology Program (NTP) has
initiated MF studies (50) that will attempt
to replicate the results obtained by the
Loscher group. These NTP studies will, in
addition, extend the exposure duration to
26 weeks and slightly vary other aspects of
the protocol. The NTP studies will also
examine effects ofMF exposure on noctur-
nal melatonin levels and ornithine decar-
boxylase activity, replicating the reports
cited above from the Loscher group.
RatLiverFoc Model
The rat liver foci system is the animal
model most commonly used for the study
of multistage carcinogenesis in extra-
epidermal tissues. The model has been com-
prehensively reviewed by Pitot (51), Dragan
and Pitot (52), and Farber (53). The fol-
lowing summary has been compiled primar-
ily from these reviews. Development ofthe
model stemmed from observations in the
1960s and early 1970s ofhyperplastic nod-
ules in the liver and their possible role as
precursors in the development ofmalignant
neoplasia. Since that time, several model
protocols have been described using altered
hepatic foci (AHF) in assays examining the
stages ofhepatocarcinogenesis in the rat.
The most commonly used protocol
requires a mitogenic stimulus, usually a par-
tial hepatectomy, in conjunction with a sin-
gle subcarcinogenic dose of an initiator
(often diethylnitrosamine [DEN]) for max-
imal sensitivity (54). (The assay can also be
done in neonates, which do not require
external mitogenic stimulation.) Mito-
genesis is believed to permit fixation by
replication ofDNAlesions produced bythe
inducer prior to repair. Other factors may
also be involved, such as chromatin accessi-
bility to the carcinogen. The parameters
most commonly quantified are the number
ofAHF, the volume percentage ofAHF in
liver, and a phenotypic fingerprint ofthe
AHF, usually determined by use ofenzyme
marker or immunohistochemical assays.
Pitot et al. have also described a methodol-
ogy for quantitatively distinguishing the
initiating and promoting potential ofagents
tested bythis protocol (55).
In this model system, treatment with an
initiator (usually DEN) at a subcarcino-
genic dose will not result in the appearance
of AHF unless a promoter is present.
Chronic treatment with a promoter follow-
ing initiation results in clonal growth to
AHF, but only a small fraction ofinitiated
cells develop into AHF. Ifthe promoter is
removed, the population ofAHF decreases,
but does not disappear altogether. The per-
sistence ofsome AHF could be due to the
numerous endogenous factors known to act
as promoters ofhepatocarcinogenesis (see
discussion below). Progression, believed to
involve additional genetic events, results
ultimately in malignant neoplasms, which
may manifest as malignant foci within exist-
ing AHF. Only a small fraction ofAHF
actually progresses to malignant neoplasia.
There are considerable morphologic
variations in AHF, which are identified
using a number ofhistological, histochemi-
cal, and immunohistochemical techniques.
Altered gene expression has been detected
in AHF using more than 40 different
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Table 5. Tests of magnetic fields in carcinogenesis bioassays.a
Test system Rodent strain Initiator/(promoter) EMFexposureb Results reported by authors Reference
Rat mammary gland
Co-initiation/promotion Rats (strain not
specified)
Sprague-Dawley
(18/group)
Sprague-Dawley
(18/group)
Sprague-Dawley
(36/group)
Sprague-Dawley
(99/group)
Sprague-Dawley
(99/group)
Sprague-Dawley
(99/group)
Sprague-Dawley
(130/group)
Rat liverfocus
Promotion
Co-promotion/
co-initiation
Mouse skin
Promotion
NMU 20 JT, 50 Hz ac or dc, 0.5 or
3 hr/day exposure for2 years
DMBA 15 mT(dc)
DMBA 30 mT(50 Hz, ac) (homogeneous)
DMBA 0.3-1.0 pT(50 Hz, gradient
ac sine wave)
10 pT(50 Hz) DMBA
DMBA 50 pT(50 Hz)
DMBA 0.1 mT(50 Hz)
(homogeneous), continuous
exposure for 13 weeks
DMBA
Sprague-Dawley DEN
Sprague-Dawley DEN
Sprague-Dawley DEN (PB)
NMRI/HAN DMBA(25.6 ug)
SENCAR DMBA(2.56 ug)
SENCAR
Co-promotion SENCAR
SENCAR
SENCAR
SENCAR
DMBA
DMBA(TPA,
1 pg/week)
DMBA(TPA,
0.3 pg/week)
DMBA(TPA,
0.3 pg/week)
DMBA(TPA,
0.3 pg/week
for 23 weeks)
0.1 or0.5 mT(50 Hz); 0.1mT(60 Hz)
18.5 hr/day exposure for 13
or 26 weeks
0.5, 5, and 50 pT, or 0.5 mT(50 Hz)
Field strength not specified but
in the 0.5 pTto 0.5 mT range
(50 Hz, intermittent on/off cycle)
0.5pT or0.5 mT(50 Hz)
50 or 500 pT(50 Hz)
50 or 500 pT(50 Hz,
continuous or intermittent-
15 sec on/off)
2 mT(60 Hz)
2 mT(60 Hz)
2 mT(60 Hz)
2 mT(60 Hz)
2 mT(60 Hz), for 52 weeks
Positive: 58% (ac) or47% (dc)
increase in tumor incidence for
3 hr/day exposure groups (p<0.05)
Equivocal: 4-fold increase in
tumorweight(p<0.05)when
compared to sham controls but no
difference when compared to
reference controls
Equivocal: 65% increase in
tumors/tumor bearing animal
when compared to ref. control
(p<0.05). Notobserved when
compared to sham control or in
a second experiment
Negative, but nocturnal
melatonin reduced
Negative
Positive: statistically significant
increase in tumor incidence in
exposed animals as compared to
sham-exposed controls (p<0.05)
Positive: 50% increase in tumor
incidence (52% in MF-exposed
versus 34% in sham-exposed
controls)(p<0.05)
In progress
Predominantly negative
Positive: quantitative data and
statistical significance
not reported
Possibly inhibitory: decrease
(p<0.05) in number offoci
(34%, 0.5gT), mean focus area
(16%, 0.5 mT), andvolume of
foci (29%, 0.5 mT)
Negative
Suggestive: dose trend
(p=0.045) for intermittent
exposure groups
Negative at 22 weeks
Negative at 22 weeks
Positive: increase in rate oftumor
development in field-exposed
mice (p<0.05)
Negative at 23weeks: replication
ofStuchly et al. (80)
Suggestive positive: non-
statistically significant increase in
overall tumor incidence at 52 weeks.
Significant (p<0.03) increase in the
fraction of mice in the field-exposed
group with malignant tumors(8 of48)
compared to sham controls(1 of48)
Beniashvili etal. (39)
Mevissen et al. (40)
Mevissen et al. (40)
Loscher et al. (34)
Mevissen et al. (40,41)
Mevissen et al. (42)
Mevissen et al. (46)
Loscher et al. (43)
Baum et al. (44)
Sasser et al. (50)
Rannug et al. (57)
Rannug etal. (59)
Rannug et al. (58)
Rannug et al. (76)
Rannug etal. (77)
Stuchly et al. (78)
McLean et al. (79)
McLean et al. (79)
Stuchly et al. (80)
McLean et al. (81)
McLean et al. (82)
(Continued)
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Table 5. Continued.
Test system Rodent strain Initiator/(promoter) EMFexposureb Results reported by authors Reference
SENCAR DMBA (TPA, 0.52, 2 mT(60 Hz) Negative at23 weeks Morris et al. (84)
Mouse lymphoma
Promotion
Rat leukemia transplant
Progression
Transqenic mouse
Rat brain/ENU
Promotion
CBA X-irradiation
(0.45 Gy/min;
5.24Gyin4
fractional doses)
C57B1/6J (195- X-irradiation
450/group) (0.34-0.37Gy/min).
Total radiation
doses: 0, 350, 475,
600 R
Sprague-Dawley ENU (trans-
placental)
Long-term chronic bioassays
2-year chronic F344 rats and
B6C3F1 mice
F344 rats
F344/N rats
Mice
Exposure A: 24
second-generation mice
Exposure B: 55
third-generation mice
2 mT(60 Hz) Increased tumor incidence at
43 weeks in 0.25 pg TPAtreated
MF-exposed group
0.015 mT(20 kHz, pulsed,
sawtooth, vertical)
1.4 mT(60 Hz, circularly polarized
with 1-mT horizontal and vertical
components)
1 mT(60 Hz, continuous) (20 hr/day)
1 mT (60 Hz, intermittent, off/on
at 3-min intervals, 20 hr/day)
1.4 p1, 200 p1, 500 pT
(60 Hz)(6hr/day, 5days/week)
ENU (pimonly) 2 p1, 0.2 mT, 1 mTcontinuous
(18.5 hr/day) (60 Hz) and 1 mT
pulsed (60 Hz, 1 hr on/off cycle)
1pT, 0.1 mT, 1 mT continuous
(50 Hz) and 1 mT pulsed (50 Hz,
15 min on/off cycle)
2 pT, 20p, 0.2 mT, and 2 mT
(60 Hz)(20 hrdailyexposure)
1, 10, 100 pT(50 Hz)
2 p1, 0.2 mT, 1mTcontinuous,
18.5 hr/day(60 Hz) and 1 mT
intermittent (60 Hz, 1 hr on/off
cycle)
0.5 mT, 5 mT(50 Hz)
2, 20, 200, 2000 pT(60 Hz)
25 mT(60 Hz)(363-418 days
exposure); sham was <0.05 mT
25 mT(60 Hz)(Exposure A: 120 days;
Exposure B: 133-257 days;
exposure began prior
to conception)
Negative after lifetime exposure
(131 weeks)
In progress
Negative
Preliminary results negative
Negative
DiGiovanni et al. (85)
Byus et al. (83)
Svedenst6l
and Holmberg (108)
Babbitt et al. (109)
Sasser et al. (131,132)
Sasser et al. (132)
Thomson et al. (133)
Negative McCormick etal. (168)
In progress Repacholi et al. (169)
In progress
Negative (no effect on mortality)
In progress
Negative
In progress
Positive: 13-fold increase in
incidence of premalignant or
malignant lymphoma
Positive: limited data provided
Mandeville et al.
(188,189)
Brugere et al. (190)
McCormick et al. (195)
Yasui et al. (196-198)
Mandeville et al.
(188,189)
Mikhail and Fam (201)
Fam and Mikhail( 199)
Mikhail and Fam
(200,201)
"We do not discuss results of two electric field exposure studies that have been reported in abstract form (207,208). Results of both studies are predominantly negative, but
are difficult to evaluate without further information. bac fields are sinusoidal unless otherwise noted.
marker assays; however, all AHF do not
express all altered phenotypes. The most
commonly expressed marker is glutathione
S-transferase (GST-P), but even this is
not expressed by all AHF. Often a second
enzyme marker is also employed, usually
y-glutamyltranspeptidase (GGT).
The markers expressed are dependent
upon the promoting agent employed. For
example, the two most common enzyme
markers, GST-P and GGT, are not
expressed when peroxisome proliferator
promoters such as ciprofibrate or Wy-
14643 are employed. Also, AHF induced
byX- andy-radiation are GGT negative.
A number ofsubstances, both natural
and synthetic, have been observed to pro-
mote hepatic carcinogenesis in the rat
liver foci model. In Table 6, 46 such agents
are listed. These agents include a wide
variety ofsubstances with diverse chemical
structures and biological activities. Examples
are: hormones such as ethinyl estradiol and
prolactin; dietary or endogenous factors
such as sucrose, tryptophan, and bile acids;
free radical generating agents and antioxi-
dants; a number ofchlorinated compounds
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SENCAR
1.05, or2.1 pg)
DMBA(TPA, 0.25
or 0.5 pg, 2/week)
F344
F344
DBA/2
pimand
TSG-p53
Ep-pim-1
Fischer ENU (trans-
placental)
1-year chronic
Multigeneration
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Table 6. Examples of promoters in the rat liver foci assay.a
Hormones
Anabiol
Reference
(51)
Ethinyl estradiol (51)
Mestranol (52)
Norethynodrel (52)
Prolactin (215)
Chlorinated hydrocarbons
Aldrin (216)
Chlorendic acid (52)
Chlorobenzilate (216,217)
DDT (51,216)
Dieldrin (51,216)
Hexachlorobenzene (218)
Hexachlorocyclohexane (a, , ory) (51,216)
Lindane (218)
PCBsb (52)
TCDD (52)
Drugs and non-chlorinated pesticides
Barbital (219)
Captifold (219)
Carbamates (ethyl, hydroxypropyl, propyl,
ethylhexyl, or methyl) (220)
Cyproterone acetate (antiandrogen and
progestogen) (51)
Dipyrone (sulpyrine) (219)
Disulfiram (219)
Phenobarbital (52)
Tamoxifen (nonsteroidal estrogen antagonist) (52)
Dietary or endogenous factors
Cholic acid
Choline-deficient diet
Deoxycholic acid
Dietary fatc
Dietary sucrose
Dietarytryptophan
Glutathioned
Orotic acid
Selenium-deficient diet
Sodium ascorbate (vitamin C)d
Taurine
Free-radical generating agents and
antioxidants
Butylated hydroxyanisole
Butylated hydroxytoluenee
Diethylhexylphthalate
Nafenopin
Wy-14, 643
Miscellaneous
y-lrradiation
1'-Hydroxysafrole
Ethanolf
Ethionine
Thioacetamide
Solvent yellow 14
Thiobenzamide
Reference
(219)
(51,52)
(221)
(222,223)
(51)
(51)
(219)
(51,52)
(223)
(219)
(219)
(51,52)
(52)
(52)
(52)
(51)
(224)
(52)
(216,219)
(216)
(51)
(225)
"This table was compiled from the reviews of Pitot (51) and Dragan and Pitot (52) and primary references as indi-
cated. All results reported were obtained in rats. In most cases, DEN was used as the initiator and a partial hepa-
tectomy was employed. All substances listed were judged by investigators to have promoter activity. Substances
that were negative and inhibited the development of AHF are not included in the table. bReported negative by Ito
et al. (216). cResults are conflicting. dEffect was considered equivocal byTsuda et al. (219). "Reported positive in
Pitot (51) and inhibitory byTsuda et al. (219) and Ito et al. (216). fReported inhibitory byTsuda et al. (219).
such as aldrin, DDT, 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD), and polychlo-
rinated biphenyls (PCBs); drugs and
pesticides such as phenobarbitol and disulfi-
ram; and a variety ofmiscellaneous agents,
including y-irradiation. Thus, as for the rat
mammary model, the liver foci system is
highly sensitive to modulation by a wide
variety ofsynthetic and natural substances,
both endogenous and exogenous.
The prototype promoter in the liver
foci system is phenobarbital (PB). PB is a
strong inducer ofliver microsomal enzymes
active in detoxifying (and in some cases
activating) xenobiotics. Certain other pro-
moters ofhepatocarcinogenesis also influ-
ence microsomal enzyme activity, such as
PCBs, TCDD, hexachlorocyclohexane, and
even dietary fat and ethanol. Interestingly,
PB also has some similarities to TPA (12-
O-tetradecanoylphorbol-13-acetate) (56),
a potent tumor promoter in mouse skin.
A number ofother hepatic promoting
agents, such as polybrominated biphenyls
(PBBs) and PCBs, are hepatotoxins and
they cause rapid cell loss followed by
regenerative hyperplasia. For example, a
choline-deficient diet causes a cycle ofliver
cell loss and regeneration, which has been
described as a chronic partial hepatectomy.
Associated with this effect is the invasion of
polymorphonuclear leukocytes, a conse-
quent increase in lipid peroxidation and
reactive oxygen species, and the possible
activation ofprotooncogenes. It should be
noted, however, that some promoters in rat
liver such as estrogens, prolactin, and
sucrose appear to stimulate hyperplasia in
the absence oftoxicity.
Tests ofMagnetic Fields in the Liver
Foci System. In 1993, using the rat liver
focus assay described by Pereira (54),
Rannug and co-workers published the
results ofexperiments designed to determine
whether 50-Hz MFs promoted the devel-
opment ofchemically initiated liver tumors
(57), or acted as a cocarcinogen (58).
In the promotion experiment (57),
200 g male Sprague-Dawley rats (10/group)
were initiated with ip DEN at a dose of
30 mg/kg ofbody weight (bw) 24 hr after
they had undergone a 70% partial hepa-
tectomy. Beginning 1 week after DEN
exposure, they were exposed for 12 weeks
to either MFs or PB, which was provided in
the diet at a concentration of 300 ppm.
Two sets ofMF exposures were adminis-
tered in two separate experiments: sham, 0.5
pT and 50 pT in the first; and sham, S pT
and 500 pT in the second. The fields were
on for 19 hr/day except for weekends and
holidays, when the fields were on for 21
hr/day. After 12 weeks, tumor number and
size were assessed through analysis ofAHF
using GGT and GST-P enzyme markers.
No body weight loss or evidence of
cytotoxicity was associated with MF expo-
sure. In the first experiment, using 0.5- and
50-pT fields, slight increases were observed
in GGT-positive foci. Similar increases in
GGT-positive foci were not observed in
the second experiment. Effects on GST-P
positive foci were not observed in either
experiment. Rannug et al. (57) conclude
that the results are predominantly nega-
tive but do not conclusively rule out the
possibility ofan effect.
Recently, in abstract form, Rannug and
colleagues reported results of experiments
using the same protocol as above except
that exposure was to intermittent fields (50
Hz, sinusoidal, field strength not specified
but in the 0.5 pT-0.5 mT range) (59).
Investigators reported a higher incidence in
the exposed animals compared to sham
controls of H-ras and GST-P foci, but not
ofGGT foci. The abstract does not include
quantitative data and does not indicate
whether results were statistically significant.
In the cocarcinogen study (58), hepatec-
tomy, initiation with DEN, promotion
with PB, and tumor assays were as above
except that, unlike the promotion study,
field exposure began immediately following
hepatectomy. Thus, the opportunity was
available for the field to act during the ini-
tiation or promotion stages. Four groups
were included: DEN only, DEN followed
by PB, and two MF groups (50 Hz, 0.5 pT
and 500 pT) exposed to both DEN and
PB. No effects on the liver to body weight
ratio or bodyweight gain were noted in the
field-exposed groups. The number of
GGT-positive foci per cm3 in the livers of
animals treated with the low field (0.5 pT)
and the mean focus area and percentage
volume occupied by foci for GST-P posi-
tive foci associated with the higher field
(500 pT) were both significantly (p<0.05)
lower than controls. However, these results
may be attributable to small sample sizes
(9-10 per group) or unaccounted-for
sources ofvariability.
Summary. MF in the 0.5- to 500-pT
range does not appear to act as a promoter
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or coinitiator in this system. Additional
information on the intermittent field
exposures is not available (B Holmberg,
personal communication).
MouseSkinModel
The development ofskin tumors in mice is
a convenient and versatile model for multi-
stage carcinogenesis. This system has been
comprehensively reviewed (60-63). Human
epidemiological studies do not suggest that
EMF exposure results in dermal tumors.
However, the skin model is advantageous,
in part because of the relative ease with
which tumors can be tracked on the backs
ofliving animals. In addition, a wealth of
information has been collected on the bio-
logical properties of carcinogen-exposed
mouse skin. As a result, morphologic (e.g.,
hyperplasia), biochemical (protein kinase C
[PKC], ornithine decarboxylase activity
[ODC], growth factors), and genetic (e.g.,
ras oncogene expression) indices may serve
as markers to track tumor development and
lend insight into carcinogenic mechanisms.
The mouse skin system also has some
relevance to human skin cancer [reviewed
by Yuspa (60) and DiGiovanni (62)].
Carcinogenesis in the skin ofboth humans
and mice is a multistep process; both
processes appear to involve protooncogene
activation; and the major end point in the
mouse system, squamous cell carcinomas,
is histologically similar to squamous cell
carcinomas in humans. However, the most
widely employed model, the two-stage pro-
tocol, is highly specialized, making extrap-
olation to humans difficult. The two-stage
protocol uses DMBA as initiator and TPA,
the most active phorbol diester in croton
oil, as a complete promoter. The protocol
also usually employs specially engineered
mouse strains, particularly the SENCAR
(sensitive to carcinogenesis) mouse.
An irreversible genetic change in an epi-
dermal stem cell is believed to be associated
with the initiation stage. This mayinvolve a
point mutation in the c-Ha-ras oncogene.
TPA is believed to facilitate two steps: con-
version ofan initiated cell to a latent tumor
cell and propagation of converted cells.
Some have suggested the conversion phase
of promotion may also involve genetic
changes [e.g., Kaina (64)], though it is not
clear how this would accommodate the
observed reversibility of promotion [see
discussion in DiGiovanni (62)].
Shortly after repeated application of
TPA begins, histological and morphologi-
cal changes are observed. Toxic effects such
as edema and inflammation are observed as
soon as a few hours after TPA treatment,
followed by regenerative epidermal hyper-
plasia, an effect common to skin tumor
promoters. The mice are examined, usually
on a weekly basis, for the appearance of
tumors. The major tumor type found is
squamous cell papilloma. These tumors
appear as early as 5 to 6 weeks after TPA
application begins. Some ofthese papillo-
mas appear to regress ifTPA treatment is
terminated; however, others will sponta-
neously progress to squamous cell carcino-
mas at about 20 weeks. The eventual ratio
ofpapillomas to carcinomas appears to be
similar for different promoters, provided
comparisons are made among groups with
similar tumor burdens (65). It is thought
that one or more additional genetic events
are required for progression to malignancy.
Though not fully elucidated, the
sequence of biochemical and molecular
events in the two-stage skin model is prob-
ably more fully understood than for any
other carcinogenesis model system. The
major mechanism of action ofTPA-type
promoters appears to be their ability to bind
to and/or activate PKC. PKC is widely dis-
tributed in mammalian tissues and is
thought to be a key enzyme in signal trans-
duction pathways [reviewed in Weinstein
(66) and Basu (67)]. It has been suggested
that activation ofPKC is essential for skin
tumor promotion by TPA-type promoters.
Activation ofPKC depends on a number of
factors, not all ofwhich arewell understood.
For example, PKC is not a single enzyme,
but represents a family of isozymes (68);
enzyme activity requires phospholipid and
calcium cofactors and PKC activation
requires enzyme translocation to membrane
sites [reviewed in Blumberg et al. (69) and
DiGiovanni (62)].
A cascade ofbiochemical events associ-
ated with PKC activation includes release
of arachidonic acid, which is involved in
prostaglandin synthesis, which in turn
leads to an inflammatory reaction resulting
in an oxidative burst in inflammatory cells
[reviewed in Fischer et al. (70)] and can
result in chromosome damage mediated by
arachidonic acid metabolites [reviewed in
DiGiovanni (62)].
ODC is also induced by TPA-type
promoters as well as by other types ofpro-
moters, including benzoyl peroxide (71),
chrysarobin, okadaic acid, calyculin A
(72), and arachidonic acid metabolites
(e.g., prostaglandin E2). ODC is the rate-
limiting enzyme in the biosynthesis of
polyamines, which are required for cell
growth. ODC has been directly linked to
promotion by experiments observing
enhanced papilloma formation in the two-
stage skin model in transgenic mice over-
expressing ODC (73).
Other biochemical effects of treatment
with TPA and other promoters have also
been observed in the mouse skin system.
These include effects on DNA synthesis;
oxidative DNA damage (74); phospho-
lipid turnover; superoxide dismutase,
catalase xanthine oxidase, histidase, and
histidine decarboxylase activities; the glu-
cocorticoid receptor; epidermal keratins
and keratin expression; and synthesis and
phosphorylation ofhistones.
After TPA treatment, a loss of PKC
activity through proteolysis is also observed.
Though it is not dear how this down regu-
lation ofPKC interacts with the process of
promotion, it has been suggested that it
may be important in sustaining hyperplasia
[reviewed in DiGiovanni (61,62)].
Evidence also suggests that promotion
can be elicited in epidermal cells through
signaling mechanisms that do not involve
PKC [reviewed by Yuspa (60)]. For exam-
ple, many promoters in the mouse skin sys-
tem do not directly activate PKC. Such
promoters may interact with mechanisms
that modulate cell growth through growth
factor-dependent processes. These, in turn,
may result in the activation of PKC indi-
rectly, or may involve PKC-independent
pathways (75).
Many substances have been found to
act as promoters or co-promoters in this
model system. Table 7 lists 55 promoters
and 14 co-promoters. Though precise
mechanisms are not certain, promoters in
mouse skin can be loosely classified in sev-
eral categories: a) TPA-type promoters,
such as aplysiatoxin and teleocidin, which
share with TPA the ability to bind to PKC;
b) non-TPA-type promoters, such as
chrysarobin and thapsigargin, which do
not appear to activate PKC but induce
ODC by a distinct mechanism possibly
involving Ca2+ mobilization; c) okadaic
acid-type promoters, which bind to a
receptor that appears to be distinct from
the phorbol ester receptor; d) dietary or
lifestyle factors such as retinoic acid or
tobacco smoke; e) various peroxide free-
radical generating compounds; andf) mis-
cellaneous agents such as acetic acid, some
polycyclic aromatic hydrocarbons (PAHs),
ultraviolet light, and skin abrasion.
Co-promoters enhance TPA promotion.
Examples include agents that affect poly-
amine or cyclic nucleotide concentrations,
such as a-methylornithine, a reversible
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Table 7. Examples of promoters and co-promoters in mouse skin.a
Promoters/co-promoters
Promoters
TPA-type promoters
TPAand various derivatives (also known
as PMA (phorbol myristate acetate)
Aplysiatoxin
Croton oil
Debromoaplysiatoxin
des-0-Methylolivoretin C
Dihydroteleocidin B
Indolactam-V
N-geranyl-(+-)-indolactam-V
Oscillatoxin A
Teleocidins A(lyngbyatoxin) and B
Non-TPA-type promoters
Anthralin (dithranol; 1,8-dihydroxy-
9-anthrone)
Chrysarobin (1,8-dihydroxy-3-methyl-
9-anthrone)b
Dinophysistoxin-1
Mirex
Palytoxin
Thapsigargin (sesquiterpene lactone)d
Okadaic acid-type promoters
Okadaic acid (a polyether of a C38
fatty acid)
Calyculin A
35-Methylokadaic acid (dinophysistoxin)
Dietary/lifestyle factors
)3-Carotenec
Citrous oilsd
Dietary fat(corn oil)c
Fatty acid methyl estersd
Onion oild
Retinoic acid
Tobacco (smoke condensate)
Tobacco (unburned extracts)
Vitamin E (d/La-tocopherol)c
Peroxides
Benzoyl peroxide
Butylated hydroxytoluene peroxided
t-Butylhydroperoxided
Cumene hydroperoxided
Reference Promoters/co-promoters
(62)
(62)
(226)
(62)
(227)
(226)
(227)
(227)
(227)
(62,228)
(62)
(62,229)
(227)
(230)
(62)
(62)
(62)
(62)
(231)
(232,233)
(226)
(234,235)
(62)
(236)
(62)
(62)
(226)
(237,238)
(62)
(62)
(239)
(239)
Promoters
Decanoyl peroxide
Dicumyl peroxide
Lauroyl peroxide
Methyl ethylketone peroxided
Miscellaneous
1,4-Naphthoquinone
1-Fluoro-2,4-dinitrobenzene
5-Hydroxy-1,4-naphthoquinone (juglone)
7-Bromomethylbenz[alanthracene
Acetic acidd
Alkanes (long chain)d
Benzo[e]pyrene
Euphorbia lattices
lodoacetic acid
Pendolmycin
Phenol and derivativesd
Silica fibers
sn-1,2-Didecanoylglycerol (endogenous
ligand of protein kinase C)
Sodium lauryl sulfated
TCDD
Tween 60d
Ultraviolet light
Urethane (ethyl carbamate)
Wounding and abrasion
Co-promoters
A23187
a-Methylornithined
Chrysarobin (1,8-dihydroxy-3-methyl-9-
anthrone)
Unsaturated fatc
Flurbiprofen
Hydrogen peroxide
Indomethacin (cyclooxygenase inhibitor)
y-lnterferone
4-0-Methyl-TPA
Mezereinf
Prostaglandins E2 or F2a
Putrescine
RPA(12-0-retinoylphorbol-13-acetate)
Ultraviolet light
observed in both exposed groups as well as
in the DMBA+ TPA control.
Reference In their second promotion experiment,
Rannug et al. (77) used the more sensitive
(240) SENCAR mouse to evaluate whether the (240) intermittency of MF exposures may be a (241) determinant oftumor development. Female (240) mice were exposed to MFs a week after ini-
(242) tiation with 2.56 pg DMBA. MF exposures
(226) occurred 19 hr/day for 104 weeks and
(242) were either continuous or intermittent (15
(62) sec on, 15 sec off), at magnitudes of 50 or
(62) 500 pT. The results obtained using (226) continuous exposure conditions appear to
(226) confirm their previous negative results.
(62) However, since no tumors occurred in the
(243) continuously exposed groups, observations
(226) from their previous experiment on latency
(62) and squamous cell carcinomas could not be
(244) compared. Investigators suggest that the
(226) intermittent exposures could beweakly pro-
(62) moting, but that the interpretation is
(245) uncertain. Since the fields were turned off
(62)
(246)
(62)
(61)
(247)
(62)
(62)
(62)
(61)
(62)
(62)
(61)
(62)
(62)
(247)
(248)
(62)
'In all cases, DMBA was used as initiator. In co-promotion experiments, TPA was the promoter. Various mouse
strains were employed, including SENCAR, CD-1, NMRI, and ICR. Co-initiators and agents demonstrating inhibitory
activity are not included. This table was compiled from the reviews of Slaga et al. (226) and DiGiovanni (62) and
primary references as indicated. bAlso a co-promoter. cResults are conflicting. dWeak activity. 'Differential effects
depending upon dose. fPrimarily a Stage II promoter and is weakly active as a complete promoter.
inhibitor of ornithine decarboxylase,
which exhibits slight activity; flurbiprofen
and indomethacin, which are cyclooxy-
genase inhibitors; y-interferon; and some
prostaglandins.
Tests ofMagnetic Fields in theMouse
Skin Model Promotion assays. Two lab-
oratories have reported results ofpromo-
tion assays in mouse skin (76-79). In
Sweden, Rannug and colleagues have con-
ducted two experiments to determine
whether 50-Hz sinusoidal magnetic fields
promote DMBA-induced skin tumors
(76,77). In the first, NMRI/HAN female
mice (30/group) were exposed to magnetic
fields (50 or 500 pT, 19 hr/day) a week
after initiation with 25.6 pg DMBA (topi-
cal). No field-related differences in tumors
were observed through 103 weeks ofpro-
motion, nor was there evidence of field-
induced hyperplasia at 9, 26, or 52 weeks.
Two observations not discussed by the
authors may be ofinterest: a) figures 1 and
2 in their paper suggest a delay in the
appearance of tumor-bearing animals in
both MF-exposed groups; however, neither
result was statistically significant; and b) no
squamous cell carcinomas were observed in
the control group treated with DMBA
alone, but squamous cell carcinomas were
by mechanical relays, uncharacterized tran-
sients were present and it is unknown
whether the weak effect, ifreal, is due to
intermittent exposure or to transients.
Although there is an increase in the number
oftumor-bearing animals in both intermit-
tent exposure treatment groups, neither
increase is statistically significant when
compared to controls. When the intermit-
tent groups are combined, the results are
still notstatisticallysignificant.
Two statistical tests were significant at
the p<0.05 level: first, the comparison of
the two intermittently exposed groups to
the two continuously exposed groups; and
second, a linear regression analysis compar-
ing the cumulative number ofskin tumors
among skin tumor-bearing animals at differ-
ent dose levels ofintermittent MF exposures.
The investigators consider the linear regres-
sion test to be the stronger ofthe two results
(B Holmberg, personal communication).
Ofadditional interest is the fact that
there appears to be a decrease in the
latency period for the 500-pT intermittent
exposure group compared to the DMBA
controls. As in their previous experiment
(76), the only squamous cell carcinomas
observed were in the TPA controls and in
an MF-exposed group (500 pT).
Stuchly et al. (78) and McLean et al.
(79) exposed female SENCAR mice
(32/group) to 2 mT (60 Hz), a flux density
four times greater than Rannug et al. (76),
but for a shorter duration-6 hr/day, 5
days/week for 21 weeks, beginning 1 week
after initiation with DMBA (2.56 pg, topi-
cal). The investigators reported (79) that
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no tumors were observed at 22 weeks when
the experiment was terminated and con-
clude that, though data are limited, 60-Hz
MFs do not act as tumor promoters.
However, since the DMBA-treated con-
trols also developed no tumors over the
course ofthe experiment, weak promoter
activity could have been obscured.
Also, since mouse strains were different
and the McLean et al. (79) experiment was
terminated after only 22 weeks, compar-
isons between this result and that obtained
by Rannug et al. (76) are difficult. It does
appear clear, however, that ifthere is any
promoting effect of 50 or 60 Hz MFs in
this model system, it is weak.
Co-promotion assays. McLean et al.
(79), using the same DMBA treatment
protocol and MF exposure conditions as
above, also treated animals with TPA (1
pg/week) beginning 1 week after DMBA
treatment. The mean number of tumors
per animal at the termination ofthe experi-
ment (22 weeks) in MF-exposed and con-
trol groups were similar. However, the
authors noted a slightly earlier appearance
ofpapillomas in the MF-exposed group,
but this difference was not statistically sig-
nificant. However, the spleens from TPA-
and field-exposed mice were enlarged rela-
tive to TPA and sham-field mice and NK
cell activity associated with TPA + 2 mT
was somewhat diminished, suggesting
that the MF had caused subtle effects (79).
In addition, the positive control group
that received 2 pg TPA twice per week had
no more tumors than those groups receiv-
ing 1 pg once per week, suggesting the sys-
tem may have saturated at the lower TPA
dose, leaving no opportunity to detect a
co-promotional effect.
The same investigators undertook a
second series ofco-promotion experiments
using a lower amount ofTPA (0.3 pg of
TPA per week as compared to 1 pg per
week) (80). They reported that, compared
to the TPA-only group, the rate of tumor
development (papillomas) was signifi-
cantly greater in the TPA + 2 mT group.
Although tumor incidence and mean num-
ber oftumors per animal were significantly
increased in the field-exposed animals dur-
ing the latter part ofthe promotion period
(16 to 18 weeks), this difference was not
statistically significant by week 23 ofpro-
motion. The investigators interpreted these
findings cautiously, but concluded that the
results were suggestive of a possible co-
promotional effect ofthe MFs. Subsequent
replications ofthis experiment produced
no differences in tumor incidence at 23
weeks between treatment and control
groups associated with the MFs (81).
A recent report (82) documented results
ofthe Stuchly et al. experiment (80) from
weeks 24 to 52 during which field exposure
was maintained but TPAwas discontinued.
McLean et al. (82) describe a higher,
though not statistically significant, percent
of tumor-bearing animals in the MF-
exposed group at 52 weeks compared to
sham-exposed controls. They report that a
higher fraction ofmice in the field-exposed
group had malignant tumors (8 of48 mice)
as compared to the sham-exposed group (1
of48), a statistically significant difference
(p<0.03). Though the authors were cau-
tious in their interpretation ofthese data,
they concluded that MF exposure mayhave
accelerated progression to malignancy.
In abstract form, Byus et al. (83) have
recently reported results ofa similar experi-
ment employing either of two dose levels
of TPA 2 times/week (0.25 or 0.5 pg).
Female SENCAR mice in groups of 60
each were used, and MF exposure was 60
Hz, 2 mT, 7 hr/day, 7 days/week. DMBA
(10 nmol) was administered 11 days prior
to MF exposure. After 43 weeks of MF
exposure a higher incidence ofpapillomas
was observed in the MF-exposed group
treated with the lower dose ofTPA (52%
in the MF-exposed group compared to
30% in sham-exposed controls), but after
33 weeks there were no field-related differ-
ences in the higher TPA dosed group. The
authors conclude that the 2 mT magnetic
field may act as a co-promoter.
A co-promotion study was also con-
ducted in SENCAR mice treated with a
single subcarcinogenic dose ofDMBA and
promoted for 23 weeks with three different
doses ofTPA (0.52, 1.05, 2.1 pig) adminis-
tered twice per week (84,85). Mice were
exposed to 2 mT (60 Hz) MFs or to an
ambient field. In addition to papilloma
induction, early biomarkers of tumor pro-
motion, including epidermal hyperplasia,
PKC, and ornithine decarboxylase, were
monitored. For all three TPA doses, there
were no field-related increases in tumors,
expressed either as percent of mice with
papillomas or as papillomas per mouse.
Biochemical analyses were also negative.
Summary. Results of promotion
experiments in the mouse skin assay system
are substantially negative. Recent reports
suggest the possibility oflate or delayed
effects associated with MF exposure in
co-promotion assays. Evidence appears
negative with respect to co-promotion at
earlier time points.
Animal ModelsofHuman Leukemia
Though results are not definitive, several
epidemiological studies have pointed to the
possibility that chronic human exposure to
EMF may result in increased risk ofchild-
hood and adult leukemia (86-89).
A variety of rodent in vivo models of
human leukemia are available [e.g., see
Pattengale and Taylor (90) for review].
Most models were developed to study the
effectiveness ofpotential chemotherapeutic
drugs and to study postinitiation events in
the progression ofleukemia. In some of
these models, leukemia is initiated by
exposure to known genotoxic agents, such
as the ENUs (91), DMBA (92), or X-rays
(93). In other models, leukemia is initiated
by transplantation of leukemic cells into
nonleukemic recipient animals (94,95).
We will discuss five leukemia/lym-
phoma model systems currently in use to
test for possible carcinogenic effects ofmag-
netic fields: the mouse thymic lymphoma
model of Kaplan and Brown (93); two
leukemia transplant models [a large granu-
lar lymphocytic (LGL) cell line passaged in
F344 rats (95) and a P388 murine leuke-
mia cell line (96,97)]; and two transgenic
mouse models (98,99).
Lymphoma in Mice Preexposed to
X-rays. Over 40 years ago, Kaplan and
Brown pioneered the development of a
thymic lymphoma model in mice (93). In
the C57BI strain, which has a low (6-8%)
spontaneous incidence oflymphoma, frac-
tionated X-irradiation results in a dose-
dependent increase in thymic lymphoma
incidence. In Kaplan and Brown's original
experiments, they defined an effective X-
irradiation dose (283 roentgens) and an
optimal interval for delivery offractionated
doses (4-8 days).
This model has commonly been
employed to study the process of lym-
phomagenesis; see reviews by Haran-Ghera
and Peled (100),Janowski et al. (101), and
Boniver et al. (102). Though lymphomas
induced by this procedure are predomi-
nantly ofthymic origin, the thymus does
not appear to be the site ofinitiation. The
most compelling evidence is the observa-
tion that thymic lymphomas arise in thy-
mus grafts after transfer to thymectomized
irradiated hosts.
A complex process appears to be
involved in lymphomagenesis, including
interactions between target cells, the bone
marrow, and the thymic environment.
Irradiation apparently results in preneo-
plastic cells that then require a period of
residence in the thymus before progressing
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to lymphoma (103). The initiating events
may occur in thymic precursor cells in the
spleen or bone marrow that later migrate
to the thymus and then become neoplastic
when normal T-cell maturation is arrested.
Kaplan suggested a possible mecha-
nism, reviewed by Haran-Ghera and
Peled (100) and Janowski et al. (101),
involving multiple effects ofX-irradiation:
activation of a potentially leukemogenic
retrovirus; damage to the thymus, followed
by regeneration leading to the appearance
ofvirus-susceptible cells; and injury to
bone marrow, preventing repopulation of
healthy thymocytes.
Janowski et al. (101) have reviewed the
role played by viruses in this process. A
retrovirus, the radiation leukemia virus
(RadLV) can be isolated from cell-free
extracts of murine thymic lymphomas
induced by X-rays. RadLV is an endoge-
nous C-type oncovirus (104). It is thymo-
tropic and gains potency on serial passage.
It has been suggested, since recombinant
proviruses are not detected in the majority
ofX-ray induced thymic lymphomas until
after further clonal growth in vitro or fur-
ther tumor development after in vivo
transplantation, that proviruses may be
involved in tumor development subsequent
to initiation.
Activated N- or K-ras oncogenes have
also been detected in most X-ray-induced
thymic lymphomas and it has been sug-
gested that somatic mutations at the ras
locus could be causally involved. Also per-
haps associated with neoplastic progression
is the observation that trisomy ofchromo-
some 15 is frequently associated with X-
ray-induced thymic lymphomas in the later
stages ofdevelopment.
In general, it appears that X-irradiation
initiates hematopoetic cells, which are then
promoted to a neoplastic state. As origi-
nally suggested by Kaplan (105), events
induced by irradiation are also probably
involved in the promotion process. Thus,
X-irradiation could interfere with physio-
logical differentiation signals in the thy-
mus, rendering the cells more likely to
continue on a path toward neoplasia.
The model may be useful for studying
postinitiation processes since manipulation
of the protocol apparently can uncouple
initiation and promotion' stages. Thus,
interferon (106) and exogenous cytokines
[reviewed by Boniver et al. (102)] can inhi-
bit postinitiation processes and increased
immune impairment (100) or treatment
with urethane (107), can enhance it. Also, it
has been suggested that some leukemogenic
agents could exert their transforming effects
without necessarily also conferring on the
initiated cells the ability to proliferate inde-
pendendy (100). Thus, split-dose X-irradia-
tion (using the Kaplan and Brown protocol)
acts as a complete carcinogen, inducing
both initiation and postinitiation events.
However, infection with an induced endo-
genous provirus, or treatment with a coleu-
kemogenic agent, may be necessary for
neoplastic development after treatment with
weak leukemogenic agents. For discussion,
see Haran-Ghera and Peled (100).
Because EMF is unlikely to act as an
initiator, this model may provide a means
to ask whether it can interact with the
thymic microenvironment to modulate
postinitiation events in initiated preleu-
kemic cells. In this regard it may be of
interest to use a protocol involving either
lower doses ofX-irradiation or weaker
leukemogenic agents to focus the protocol
more clearly on postinitiation events.
Tests of magnetic fields in the
mouse lymphoma/X-irradiation model.
Svedenstal and Holmberg (108) exposed
female CBA mice to sawtooth 15-pT peak
to peak pulsed vertical 20-kHz MFs for
their lifetime (up to 131 weeks). MF expo-
sure began immediately after the first of
four X-ray exposures and continued for the
lifetime of the animals. The total X-ray
dose rate was 0.45 Gy/min and total irradi-
ation was 5.24 Gy, divided into four expo-
sures administered at 4-day intervals. Blood
cell counts and the incidence ofthymic and
nonthymic lymphomas were recorded.
The data show a significant increase
in the number of leukocytes in exposed
animals, whether or not animals were
treated with X-rays. Svedenstal and
Holmberg indicate these high values were
due to extreme values in two animals. No
statistically significant effects on thymic or
nonthymic lymphoma incidence were
observed in the groups exposed to MFs.
While this study is ofinterest, it is diffi-
cult to interpret for two reasons. First, as
the investigators indicate, experimental and
control groups were started at different
times and used different batches of ani-
mals. The tumor incidences reported for
each experimental group, including
controls, were totaled over three to four
subgroups that entered the study at times
differing by as much as a year. Comparisons
between such nonconcurrent experimental
and control groups should be made with
caution. Second, as the investigators also
point out, the X-ray-induced incidence of
lymphoma was higher than expected
(66%), resulting in limited statistical power
ofthe assay.
Babbitt et al. (109) are conducting a
large study (195-450 mice/group) using
the Kaplan model, in which each of four
groups ofmice receiving fractionated ioniz-
ing radiation (Cobalt 60) at 0, 350, 475,
and 600 R, will be chronically exposed to
either 60-Hz circularly polarized MFs with
1 mT horizontal and vertical components,
or to a sham field. MF exposure began on
the first day ofirradiation and will continue
18 hr/day for the 2-year duration of the
study. Evaluation will be by morphologic
and histopathologic analyses.
Leukemia Transplant Models. Large
granular lymphocytes passaged in vivo
in F344 rats. Large granular lymphocytes
(LGL) comprise 10 to 15% of peripheral
blood mononuclear cells in rats. A class of
leukemias involving the proliferation of
LGL occurs in both humans and rodents.
LGL in humans are believed to be NK cells
or in vivo activated cytotoxic T lympho-
cytes (110). Stromberg (111) and Rosol
and Stromberg (112) have pointed out the
morphologic, biochemical, and functional
similarities between human and rat LGL
and have also indicated similarities in the
clinical profiles of the LGL leukemias in
humans and the Fischer rat.
Stromberg et al. (113) proposed a
passaged leukemia cell model in which leu-
kemic cell lines are maintained in vivo by
serial transplantation in male Fischer F344
rats. Dieter et al. (114) have employed this
model as a short-term assay for potential
antileukemic agents. In their procedure,
passaged cells are harvested and injected
subcutaneously into 8-week-old syngeneic
recipients. The chemical to be tested is
usually administered at the time of trans-
plantation. After 70 days, the animals are
sacrificed and hematological, histological,
biochemical, and clinical data are used to
characterize the progression of the dis-
ease. The major parameters reported are
spleen weight, white blood cell count, and
hematological indices.
The morphological, clinical, and bio-
chemical characteristics of the leukemia
response in transplant recipients is similar
to the spontaneous disease in Fischer rats
(115,116). Furthermore, the protoonco-
gene associated with the spontaneous
disease (c-fins) is found in transplant recip-
ients (117). The onset ofthe disease (118)
is characterized by LGL infiltration of the
spleen resulting in splenomegaly and,
often, infiltration of the bone marrow.
This is usually accompanied by severe
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hemolytic anemia, enlargement oflymph
nodes, and a number ofother well-defined
clinical features (111,119).
Because this model employs previously
initiated neoplastic cells, biological factors
that may be involved in progression are of
primary interest. Proliferation ofhemato-
poetic cells appears to be controlled by a
variety ofgrowth factors. Increasing evi-
dence favors an autocrine growth model
wherein abnormal production ofa growth
factor by a cell with receptors for that factor
results in neoplastic proliferation (120,121).
In fact, it has been shown that the product
ofthe oncogene c-fins, which is associated
with LGL leukemia in Fischer rats, is
related to the receptor for the mononuclear
phagocyte growth factor (CSF-1) (122).
It is also of interest that dietary restric-
tion (DR) significantly slows the prolifera-
tion ofLGL leukemia cells in the F344 rat
transplant model (123), as it does with
many other types ofneoplasms (124).
The model was used to test five sub-
stances previously found to decrease or
increase the incidence ofleukemia in 2-year
chronic carcinogenesis bioassays in F344
rats (114). All five substances had activities
in the short-term transplant model similar
to those seen chronically. While these results
are ofinterest, they may not be generalizable
to the LGL system as usually employed.
Dieter et al. (114) used a slow growing
LGL cell line and observed only small
increases in leukemia end points in trans-
plant controls as compared to nontransplant
controls. For example, the difference Dieter
et al. (115) observed in white blood cell
count in nontransplant controls and trans-
plant controls was less than 2-fold as com-
pared to the more than 10-fold increases
later reported by Dieter (125) and by others
(95,126). Perhaps not surprisingly, the
result reported by Dieter et al. (114) for one
ofthe five substances, 2,4,6-trichlorophenol
(TCP), was not replicated in a recent report
from a different laboratory (126).
P388 Leukemia Cell Transplant
Model Since 1968, the P388 leukemia cell
transplant model has been a standard pre-
screen used in the preclinical drug testing
program of the National Cancer Institute
(NCI) (96,127). P388 is a rapidly growing
leukemia cell line that is highly sensitive to
a wide spectrum ofcytotoxic drugs. This is
an advantage in that the assay is relatively
simple to perform, is of short duration
(20-30 days), and few cytotoxic drugs are
undetected by the system. However, the
extreme sensitivity ofthe system is also con-
sidered to make it less clinically relevant
than other slower growing tumors [e.g., see
Budel et al. (128)], or tumors that have
drug resistance markers characteristic of
many clinical forms ofleukemia [see Yang
et al. (129)].
In a typical chemotherapeutic drug
prescreening assay, about 106 P388 cells, as
diluted ascitic fluid, are injected intraperi-
toneally in BDF1 or CDF1 mice (six ani-
mals/test group). Drug treatment begins
on the day after implantation. The lifespan
of treated animals is usually less than 3
weeks (97). Typically, the only parameter
monitored is survival time. An increase of
at least 25% in median survival time over
controls is considered a positive result. An
agent positive in this prescreen is then
tested further in other screening assays
prior to entering clinical trials (130).
Over the years, the drug-testing
program of the NCI has screened more
than 300,000 chemicals using this system.
As of 1984, some 10,000 compounds were
routinely tested each year (130).
Tests of magnetic fields in leukemia
transplant models. Largegranular lympho-
cyte model. Results of tests of 60-Hz
manetic fields using the LGL model have
recently been reported in abstract form
(131,132).
In these studies, groups of 18 animals
were exposed to 1.0 mT fields (20 hr/day)
beginning at the time of injection, with
LGL leukemic cells, with exposure continu-
ing for the duration ofthe experiment. The
first set ofexperiments (131) used continu-
ous fields and the second (132), in addition
to replicating the continuous exposure con-
dition, also tested intermittent fields (off/on
at 3-min intervals). The 1996 study also
examined effects at a 10-fold smaller inocu-
lum in addition to replicating the original
experiment using 2.2x107 cells. Controls
were a null energized field (about 2 pT)
(only in the 1994 study), ambient controls
(0.1 pT or less), and y-irradiated positive
controls. Blood samples were taken weekly
for 10 weeks from serially sacrificed animals
or from animals following death. Hemato-
logical end points included Hb (hemoglo-
bin) concentration, RBC (red blood cell),
differential WBC (white blood cell), platelet
cell counts, peripheral blood tumor cell
counts, and other parameters. No significant
exposure-related differences were observed
in hematological parameters or mortality in
either study. Further analysis ofperipheral
nucleated blood cells and survival data for
the 1996 studyare in progress.
P388 model. Thomson et al. (133) used
the P388 leukemia transplant model in
female DBA/2 mice to examine 60-Hz 1.4,
200, or 500 pT MF effects. Groups of
10 mice each were implanted with 1 x 105
P388 cells at about 8 weeks ofage and then
exposed until death (about 2 weeks) to
the MFs (6 hr/day, 5 days/week) beginning
2 to 3 hr after the implant. Sham-exposed
controls, both nonimplanted and implanted,
were run in parallel to the MF-exposed
groups. End points determined were sur-
vival, spleen weight, and body weight. No
statistically significant effects were reported.
Though no effect on the incidence or pro-
gression of P388 leukemia was apparent,
this model, because of the rapid develop-
ment of leukemia, may not be sensitive
enough for the detection ofweakeffects.
Transgenic Models. Transgenic models
utilize specially constructed mouse strains
that are constitutive for the expression of
specific oncogenes. A number of models
are available, which express most classes of
oncogenes; see reviews byAdams and Cory
(134), Hanahan (135), and Connelly et al.
(136). These classes include genes encoded
for growth factors, growth factor receptors,
proteins believed to be involved in signal
transduction pathways, cytoplasmic pro-
tein kinases, genes that affect transcription
or cell division, and tumor suppressor genes
[reviewed byAdams and Cory (134)].
In this briefdiscussion we will focus on
two murine transgenic models currently in
use to test for potential effects ofmagnetic
fields on lymphomagenesis: the ENU/Pim-1
and TSG-p53 systems.
ENUIPim-1 system. The Pim-1 onco-
gene was originally discovered because it is
activated by the Moloney murine leukemia
virus in conjunctionwith induction ofT-cell
lymphomas (137). This oncogene encodes
two cytoplasmic protein kinases (138) and
is highly expressed in many human hem-
atopoietic malignancies (139,140). It is pri-
marily expressed in hematopoietic tissues
and gonads (141,142).
About 10% of transgenic mice over-
expressing the Pim-1 oncogene in lymphoid
cells develop T-cell lymphomas (143). If
such mice are treated at day 15 after birth
with initiating doses of ENU as low as 15
mg/kg bw (ip) and followed for 34 weeks,
the latency period is significantly decreased
and the frequency oflymphomas is greatly
increased (98). Overexpression ofc-myc is
observed in the ENU-induced lymphomas
(but not in spontaneous tumors) in the
Pim-1 strains, suggesting that both c-myc
and Pim-1 are involved in lymphomagenesis
in this system. Studies not involving ENU
with double transgenic mice containing
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both Pim-1 and myconcogenes also suggest
a strong synergism between these two
oncogene classes in both B- and T-cell
lymphomagenesis (144).
Studies using either Ep-Pim-1 strains,
which overproduce Pim-1, or Pim-1-defi-
cient strains, have sought to elucidate the
mechanism ofoncogenesis induced by Pim-
1. Although a precise mechanism is still
unclear, several studies have provided clues.
First, Pim-1 does not appear to increase
susceptibility to mutagenesis, at least as
measured by the micronucleus assay (145).
Second, Pim-1 may play an important role
in growth signaling from the erythropoietin
receptor (146), or in modulation of the
interleukin-3 (IL-3) signal transduction
pathway (147). In fact, Pim-1 is induced
by IL-3 (148). Third, Pim-1 may inhibit
apoptosis (149).
The p53 system. The complex func-
tions ofp53 have recently been thoroughly
reviewed (150-152). p53 is a tumor sup-
pressor gene. Its inactivation is associated
with the progression stage ofcarcinogenesis
(153-155) and with enhanced genetic
instability (99). p53 induces transcription
of a number of genes and is part of a
checkpoint system that prevents damaged
DNA from being replicated by arresting
the cell cycle in GI [reviewed by Hartwell
and Kastan (151)]. Inactivation of this
checkpoint is believed to enhance genomic
instability, thus furthering the likelihood of
cellular progression to malignancy (99).
The association ofp53 inactivation with
progression is based on studies using the
multistage mouse skin model (153), ery-
throleukemia development in mice (154),
and observations in humans (155). As
reviewed by Donehower and Bradley
(150), p53 may also act prior to the pro-
gression stage in some other animal models
ofcarcinogenesis.
The interactions ofp53 with cellular
processes is complex and incompletely
understood. p53 accumulates in the cyto-
plasm during G1 and migrates to the
nucleus when the S phase begins (156). It
appears to regulate transcription by binding
directly to DNA in concert with certain
coactivators, transmitting a transcription
activation signal in a transcription initia-
tion complex (157). Enhanced susceptibil-
ity to tumorigenesis has been linked to
inhibition ofthis DNAbinding capacity.
p53has also been linked to maintenance
of asymmetric division kinetics of renew-
ing cells, the primary mode ofcell division
in adults (158), apoptosis (159,160),
DNA repair (161), gene amplification
(162), and mutator and hypermutable
phenotypes (163).
Mutations at thep53locus are common
in a wide variety ofhuman cancers (164).
It is interesting that both transgenic mice
overexpressing a mutated form ofp53
(165) and p53-deficient mice (99) have
enhanced susceptibility to the development
of spontaneous tumors, particularly soft-
tissue tumors and lymphomas. Almost
80% ofp53-deficient mice develop malig-
nant lymphomas involving a variety of
organs, including the thymus, heart, lung,
spleen, liver, kidney, and brain by about 5
months ofage, compared to 30% oftrans-
genic mice expressing a mutated form of
p53 in 18 months (165). The characteris-
tics of tumors observed in p53-deficient
mice are similar to those ofhuman child-
hood tumors, which has led some to sug-
gest that these mice may be useful models
for childhood cancers (166). Mice het-
erozygous for p53 are also susceptible to
spontaneous tumors, but less so than the
homozygous mice. It has been suggested
that the longer latency period and the
lower spontaneous tumor frequency in het-
erozygous mice make them more suitable
for use in carcinogenesis test protocols
(166). This suggestion was borne out in
comparative tests ofhomozygous and het-
erozygous strains using dimethylnitrosa-
mine (DMN) as an initiator (166). Both
p53 transgenic mice andp53-deficient mice
are also more sensitive to carcinogenesis
induced by ionizing radiation (167).
Tests ofmagnetic fields in transgenic
systems. Studies have recently been com-
pleted using Pim-1 and TSG-p53 trans-
genic mice to assess the potential effects on
lymphomagenesis ofcontinuous exposure
(18.5 hr/day to 60-Hz MFs at 0, 2 pT, 0.2
mT, and 1 mT) or intermittent exposure
(1 mT, 1-hr on/offcycle) (168). Animals
(30-40 of each sex) were used at each
exposure condition and parameters evalu-
ated were lymphoma incidence and latency
period. No increases in lymphoma incidence
over controls were observed under any MF
exposure condition.
Repacholi et al. (169) recently presented
an in-progress report of a carcinogenicity
study using E1i-Pim-1 transgenic mice in
which groups of about 100 mice were
exposed to 50-Hz continuous magnetic
fields of 1 pT, 0.1 mT, and 1 mT and
intermittent fields of 1 mT (50 Hz, 15 min
on/off) 20 hr/day for up to 18 months.
The final evaluation will include a full his-
topathological analysis as well as immuno-
phenotyping oflymphoid cells.
RatBrainModel
Anumber ofhuman epidemiological studies
have reported an association between expo-
sure to EMF and increased brain cancer
risk, most recently a large study ofelectrical
utility workers (170). There are a number
of brain cancer animal models available,
including those involving carcinogen- or
virus-induction, cell or tissue transplanta-
tion, and transgenic systems; see reviews by
Peterson et al. (171) and Kleihues et al.
(172). In this briefsummary, we will focus
on an ENU-induction model in rats.
The effectiveness of the nitrosoureas,
particularly MNU and ENU, in inducing
brain cancer after transplacental administra-
tion, was demonstrated some 25 years ago
(173). The nitrosoureas induce gliomas in
the brain or spinal cord, most commonly
oligodendrogliomas and Schwannomas (also
called neurinomas) in peripheral nerves.
The nitrosoureas are mutagens that
alkylate guanine at the 06 position. Their
efficiency in inducing brain tumors may be
due to the slow repair ofthese lesions in the
brain [reviewed byMaekawa and Mitsumori
(174)]. Target genes for ENU mutagenesis
have not yet been identified with certainty.
However, mutations in tumor suppressor
genes have been associated with brain
tumors in humans [reviewed in Briistle
et al. (175)]. These could be target genes
for ENU mutagenesis. A variety of onco-
genes have also been associated with malig-
nant gliomas [reviewed by Peterson et al.
(171), Radner et al. (176), and Bigner
and Vogelstein (177)] and these are also
candidate target genes for ENU.
As is the case for humans, spontaneous
tumors in the rat brain are relatively rare,
though there is considerable variation in
both incidence and tumor type among rat
strains (174). The frequency and type of
neurogenic tumors produced by the nitro-
soureas also are quite variable depending
upon the route of administration, rat
strain, and age. Newborns and neonates are
particularly sensitive to induction. It has
been proposed that target cells are either
embryonal matrix cells or oligodendrocyte
precursor cells [reviewed by Maekawa and
Mitsumori (174)].
Indirect evidence suggests that carcino-
genesis in rat brain is a multistage process
(175). For example, 06-ethylguanine
lesions in brain are similarly induced and
repaired in two strains of rats with signifi-
cantly different sensitivities to neurogenic
tumor induction by ENU (178), suggest-
ing that 06-ethylguanine is not sufficient
for tumorigenesis.
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In a typical protocol, ENU is adminis-
tered either to female rats in the third week
ofpregnancy [e.g., iv, 10 mg/kg (179)] or
to newborn rats [e.g., sc, 17 mg/kg (180)].
If initiator treatment was transplacental,
promoter treatment begins in newborn
pups; if initiator treatment was postnatal,
promoter treatment begins several weeks
after initiation. Early lesions appear at
about 2 months ofage following transpla-
cental ENU exposure. Tumor incidence
and histopathology are evaluated after
about 6 months.
The heavy metal zinc acetate (180) and
the skin tumor promoter TPA (181) have
been reported to increase the incidence of
brain tumors after transplacental adminis-
tration ofENU, though others (179) have
not considered these results definitive.
Several substances including the drugs
buformin [reviewed by Maekawa and
Mitsumori (174)], the cytokine TNF-a
(182), and NGF (nerve growth factor)
(183) have an inhibitory effect on transpla-
cental ENU-induced neurogenesis. Chronic
stress (184), which has been associated
with enhancement ofsome forms ofcancer,
and phenobarbital (185) were not observed
to increase the incidence oftransplacental
ENU-induced brain tumors in rats.
Though the rat model system has some
similarities to the human disease, there are
also significant differences. Thus, the pri-
mary tumor types induced in the rat brain,
particularly oligodendrogliomas and astro-
cytomas, also occur in adult humans.
However, in humans, there is an increased
incidence ofbrain cancer in childhood that
decreases in early adulthood and is not
observed in rats unless they have been
exposed transplacentally to carcinogens
[reviewed by Maekawa and Mitsumori
(174)]. (Some have suggested the young-
age peak in humans maybe due to prenatal
carcinogen exposure.) There are also signif-
icant sex differences in human brain cancer
(186) but not in rats (174). Additionally,
the predominant childhood brain tumor
type in humans is not induced by the
nitrosoureas in rats. Rat esthesioneuroepi-
theliomas, which are induced by nitro-
samines but not the nitrosoureas, are
histologically similar to the human tumors
and have been suggested as a model for
human cancer (187). (However, this
tumor does not occur in the brain, but in
the sensory epithelium ofthe nasal cavity.)
Tests ofMagnetic Fields in the Rat
Brain System. Tests are currently in
progress using the ENU transplacental
model in Fischer rats. Experiments are
planned in which animals will be chroni-
cally exposed 20 hr/day to 2, 20, 200, and
2000 pT (188,189).
Brugere et al. (190) report, in abstract
form, no effect on survival time after
chronic treatment ofweanlings with homo-
geneous 50-Hz magnetic fields of 1, 10, or
100 pT. In this experiment, Sprague-
Dawley females were treated with ENU (50
mg/kg, iv) on day 19 of pregnancy and
weanlings (60 males and 60 females in each
exposure group) were exposed to MFs for
their lifetimes. Though the authors con-
clude from these results that there was no
effect on ENU-induced brain tumors, this
conclusion is unwarranted without support-
ing histopathological analysis. Investigators
do not state whether any animals in the
studyhad central nervous system tumors.
Two-year ChronicBioassays
in Rat andMice
Under the auspices ofthe NTP, more than
400 chemicals have been evaluated for car-
cinogenic potential using 2-year chronic
bioassays in F344 rats and B6C3Fj mice
over the past 15 years (191). NTP studies
specify a rigorous methodology (192,193),
which, while not uncontroversial [e.g.,
Ames and Gold (194)], is considered to be
the most thorough rodent carcinogenesis
bioassay available. The protocol is primarily
directed at detection of initiator activity.
However, since the animal strains employed
develop a variety ofspontaneous tumors,
the protocol is also suitable for detection of
agents capable of promoting neoplastic
processes involved in spontaneous neoplasia.
In the NTP protocol, relatively large
numbers ofanimals ofboth sexes in both
species are exposed to at least two doses of
test substance in addition to a sham con-
trol. The animals are closely monitored
over the course of their lifetimes for sur-
vival, body weight, and clinical signs of
neoplasia. At death, or at termination ofthe
experiment, all animals are evaluated by
complete necropsy and histopathological
examinations.
Tests of Magnetic Fields Using
Chronic Bioassay in Rats and Mice.
(See also "Tests of Magnetic Fields in
Lymphoma/X-Irradiation.") Studies to
assess potential carcinogenic effects ofMFs
using the standard NTP 2-year chronic
bioassay protocol have been initiated
(188,189,195). In the McCormick et al.
study (195), some 2000 male and female
F344 rats and B6C3F1 mice will be
exposed continuously (18.5 hr/day for 2
years) to 60-Hz MFs at 0, 2 pT, 0.2 mT,
or 1 mT in exposure groups of 100 animals
each. One intermittent exposure to 1 mT
(1 hr on, 1 hr off) will also be included.
Exposure will be completed in 1996 and
final results are expected in 1998.
In the Mandeville et al. study (188,189),
5 groups of 50 female F344/N rats will be
exposed 20 hr/day from birth to 2 years of
age to linear sinusoidal continuous-wave
60-Hz MFs at sham plus four intensities
(2, 20, 200, and 2000 pT). Histopathology
will be performed on all tissues following
NTP protocols.
Yasui et al. (196-198) reported, primar-
ily in abstract form, that continuous expo-
sure ofF344 rats (48 male and 48 female)
for 2 years to 0.5 mT or 5 mT 50-Hz sinu-
soidal alternating MFs did not result in a
statistically significant difference in neoplas-
tic end points compared to sham-exposed
controls. Analysis involved a comprehensive
histopathological examination of organs,
including hematological tests. Unfortu-
nately, there is insufficient detail in pub-
lished reports for athorough evaluation.
Mikhail and Fam have reported, mostly
in abstract form, that continuous multigen-
eration exposure ofmice to a 60 Hz, 25-mT
MF results in highly statistically significant
increases in lymphoma in exposed animals
compared to unexposed controls (199-201).
The authors indicate that positive results
were obtained in separate experiments
involving 24 second-generation mice
exposed for an average of 120 days, 55
third-generation mice exposed for 133 to
257 days, and 41 third-generation mice
exposed for 363 to 418 days. Unfortunately,
there is insufficient detail in published
reports for an adequate evaluation.
Conclusion
We have reviewed eight major animal
models currently in use to test for potential
carcinogenic properties of EMF (Table 1).
For each model we have discussed its devel-
opment, multistage characteristics, relevant
biological mechanisms, and test protocol
characteristics (summarized in Table 2).
We have also compiled a referenced list
ofsubstances that have tested positive for
promoter activity in three widely used
models (Tables 3,6,7).
The models we have reviewed represent
an imaginative and diverse collection of
methods for detecting agents capable of
enhancing the carcinogenic process. With
the exception of the 2-year chronic bioas-
say protocols, the models discussed focus
primarily on detecting agents that affect
the promotion or progression stages of
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carcinogenesis. Some ofthese systems use
engineered strains ofrodents (e.g., SEN-
CAR or transgenic strains ofmice). Others
result in assay end points that have uncer-
tain relevance to malignant disease (e.g.,
AHF, papillomas), or may be dependent
upon a highly specialized protocol (e.g., the
two-stage mouse skin protocol involving
use ofboth an initiator and promoter).
It will be important to continue to
address the relevance ofresults in these sys-
tems to human cancer risk. A number of
factors involving species differences, the
relationship of the induced neoplasm to
human disease, and protocol-specific
effects must be considered.
Tests ofMFs that are completed or in
progress in these systems have also been
reviewed (results are summarized in Table
5). These include all completed animal
studies and those currently in progress that
use animal cancer models to test for the
effects ofstatic and low-frequency EMF.
Nearly all studies cited used MFs at the
common power delivery frequencies of 50
or 60 Hz. These frequencies fall in the
extremely-low-frequency spectrum, defined
as 3 Hz to 3 kHz. A few other studies used
either 60-Hz electric fields, static MFs, or
MFs at frequencies of 15 to 20 kHz, typi-
cal ofvideo display terminals. Typical
time-averaged residential exposures are
around 0.1 fiT and seldom exceed 0.5 iT.
However, some individuals, especially in
occupational environments, are occasion-
ally exposed to much higher fields-up to
1 to 2 mT. These high exposures usually
involve only a portion ofthe body. Most
animal studies use MFs on the order of
1 mT, which are 3 to 4 orders of magni-
tude higher than average residential expo-
sures, but in the upper range ofoccasional
human exposures.
Though most results are negative,
weakly positive or equivocal results involv-
ing one or more test parameters have been
reported in several systems: the rat mam-
mary gland system (39,40,43,44,46); the
rat liver focus system (59); and the mouse
skin system (77,80,82,83). It may be of
interest that positive effects reported in
both the rat mammary gland and the
mouse skin systems suggest that EMF at
low flux densities may enhance the latter
stages of carcinogenesis. The positive
reports of Fam and Mikhail (199) and
Mikhail and Fam (200,201) are very diffi-
cult to evaluate (see "Two-year Chronic
Bioassays in Rats and Mice"). As shown in
Table 5, some experiments are still in
progress [mouse lymphoma (109), trans-
genic mouse (169), rat brain (189), and
2-year chronic bioassays (189,195)].
It should be noted that interpretation
of negative results in EMF carcinogenesis
studies could be complicated by the possi-
bility ofwindow effects, though their exis-
tence is controversial; see Bowman et al.
(202) for discussion. If EMF effects on
carcinogenesis were to involve such phe-
nomena, it would be difficult to conclude
that negative results at relatively high expo-
sures implied negativity at lower exposures,
such as is routinely assumed for chemical
effects on carcinogenesis.
The interpretation of the weakly posi-
tive results discussed above is complex.
First, results reported positive are at a weak
level ofstatistical significance (p<0.05).
That such results could be the result of
uncontrolled variability is a concern, par-
ticularly because ofthe sensitivity of the
promotion response to modulation by
numerous endogenous and exogenous sub-
stances. It is therefore especially important
that weakly significant results be indepen-
dently corroborated before any definitive
conclusion is drawn. Second, in some
cases, positive results are in one measured
parameter and not in other related parame-
ters measured in the same assay. Taken
together with the weak (p<0.05) statistical
significance, the absence of an effect on
more than one related parameter also tends
to decrease confidence in the validity ofthe
positive results.
The results reported by Loscher and his
colleagues require special commentary.
These authors have provided a series of
experimental neoplastic and related bio-
chemical evidence that they believe
strongly suggests that weak 50-Hz MFs in
the 50 to 100 pT range act as a promoter
or co-promoter in the rat/DMBA mam-
mary carcinoma model. It is important to
note that their experiments are currently
undergoing independent replication.
Though testing is incomplete, based on
results so far available it appears that any
effect of EMF in these model systems is
weak. This should be carefully considered
in the protocol design of future studies.
Realistically, it may be difficult to fine tune
these assays enough to demonstrate unequi-
vocally the presence or absence of very
weak effects. It may therefore be advanta-
geous to expand end points in these sys-
tems to include biochemical or biophysical
parameters relevant to possible carcino-
genic mechanisms of EMF. Because EMF
does not appear to have genotoxic potential
at environmentally relevant exposures
[reviewed by McCann et al. (203) and
Murphy et al. (204)], any carcinogenic
potential would most likely involve
nongenotoxic pathways [for discussion see
Cohen and Ellwein (205) and Kavet
(206)]. Further, since EMF does not
appear to have toxic effects that could lead
to regenerative hyperplasia, any such effect
of EMF on carcinogenesis would most
likely be through a nontoxic proliferative
stimulus mechanism.
As discussed in the text, there are many
biochemical or other parameters reflective of
biological processes known to be associated
with carcinogenesis in the different model
systems. A number ofthese parameters may
be appropriate for use in expanded test
protocols. Parameters that are also known
to be possibly associated with EMF bioef-
fects may be ofparticular interest. Examples
are effects on membrane function (such as
may affect the phospholipid-dependent
enzyme PKC), reactive oxygen species, cal-
cium ion mobilization, or the hormonal
environment (particularly melatonin).
Whereas such expanded protocols may per-
mit more definitive conclusions as to the
potential adverse health effects of EMF in
animal systems, the additional parameters
added to already complex protocols will also
raise statistical issues that will need to be
taken into account in protocol design.
NOTE ADDED IN PROOF: After this
paper was in press, Loscher and colleagues
reported that they had successfully repli-
cated the 100 pT experiment (Loscher W,
Mevissen M, Haug3ler M. Exposure of rats
to a 50-Hz, 100 pT magnetic field increases
the development and growth of mammary
tumors in a DMBA-model ofbreast cancer
replicate study. In: The Annual Review of
Research on Biological Effects of Electric
and Magnetic Fields from the Generation,
Delivery & Use ofElectricity, San Antonio,
TX, November 19, 1996. W/L Associates,
Ltd., Frederick, MD. pp 7-8). In addition
the in press work ofC. Graham et al. cited
on MF exposure and plasma melatonin in
humans has been published [Graham C,
Cook MR, Riffle DW, Gerkovich MM,
Cohen HD. Nocturnal melatonin levels in
human volunteers exposed to intermittent
60 Hz magnetic fields. Bioelectromagnetics
17:263-273 (1996)].
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